A Pilot Study of the Neo-adjuvant Use of Vemurafenib Plus Cobimetinib (GDC-0973) in Patients With BRAF Mutant Melanoma With Palpable Lymph Node Metastases

Trial Profile

A Pilot Study of the Neo-adjuvant Use of Vemurafenib Plus Cobimetinib (GDC-0973) in Patients With BRAF Mutant Melanoma With Palpable Lymph Node Metastases

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2016

At a glance

  • Drugs Cobimetinib (Primary) ; Vemurafenib (Primary)
  • Indications Cancer metastases; Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Sunnybrook Health Sciences Centre
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Aug 2015 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 14 Aug 2015 According to the ClinicalTrials.gov record, status changed from not yet recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top